The Effect of Amiloride and Spironolactone in Patients With Hypertension (hass)

Erling Bjerregaard Pedersen

Status and phase: Completed; Phase 4

Conditions: Hypertension

Treatments: Drug: Spironolactone; Drug: Placebo; Drug: Amiloride

Study type: Interventional

Funder types: Other

Identifiers

NCT01388088

MED.RES.HOS.2010.02.SKM

Details and patient eligibility

About

The investigators wish to investigate the potential effects of potassium. In this study we will examine patients with hypertension and increase their potassium-levels using Amiloride and Spironolactone.

The investigators will examine the changes in the cardiovascular system using a Sphygmocor-scanner.

Full description

Purpose of the study is to examine the effect of amilorid and spironolacton on

1. Renal function (GFR, u-AQP2, u-ENaCβ, u-cAMP, u-PGE2, CH20, FENa, FEK),
2. Pulsewavevelocity, augmentation index and centralt bloodpressure,
3. Vasoactive hormones (PRC, AngII, Aldo, AVP, ANP, BNP and Endot), and
4. Ambulatory blood pressure

Enrollment: 23 patients

Sex: All

Ages: 45 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hypertension
• Age 45-70
• BMI: 18,5-30

Exclusion criteria

• Other diseases
• Drug or alcohol abuse
• Abnormal findings in the screening procedure

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

23 participants in 3 patient groups, including a placebo group

Spironolactone

Active Comparator group

Description:

Increases the level of potassium

Treatment:

Drug: Spironolactone

Amiloride

Active Comparator group

Description:

Increases the level of potassium

Treatment:

Drug: Amiloride

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo